Overdiagnosis: Causes and Consequences in Primary Health Care
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Preventive Health Care
PREVENTIVE HEALTH CARE DANA BARTLETT, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT Screening is an effective method for detecting and preventing acute and chronic diseases. In the United States healthcare tends to be provided after someone has become unwell and medical attention is sought. Poor health habits play a large part in the pathogenesis and progression of many common, chronic diseases. Conversely, healthy habits are very effective at preventing many diseases. The common causes of chronic disease and prevention are discussed with a primary focus on the role of health professionals to provide preventive healthcare and to educate patients to recognize risk factors and to avoid a chronic disease. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities. -
Colorectal Cancer Screening Algorithm
Colorectal Cancer Screening Page 1 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. This algorithm is not intended for individuals with a personal history of colorectal cancer 1. Note: Screening for adults age 76 to 85 years old should be evaluated on an individual basis by their health care provider to assess the risks and benefits of screen ing. Colorectal cancer screening is not recommended over age 85 years. TABLE OF CONTENTS Average Risk …………..………………...……………………..………………………………...Page 2 Increased Risk ………………………...…………………...………….………………………….Page 3 High Risk ………………………………………………………………………………………....Page 4 Suggested Readings …………………………………...……...………………………………….Page 5 Development Credits ………………………………………………….........................................Page 6 1 See the Colon or Rectal Cancer Treatment or Survivorship algorithms for the management of individuals with a personal history of colorectal cancer Department of Clinical Effectiveness V9 Approved by the Executive Committee of the Medical Staff on 09/21/2021 Colorectal Cancer Screening – Average Risk Page 2 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. -
Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s. -
Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: an Update for the U.S
Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force Linda L. Humphrey, MD, MPH; Steven Teutsch, MD, MPH; Mark S. Johnson, MD, MPH Screening for lung cancer is not currently increasing in epidemic proportions,3,4 with an recommended by any major medical professional estimated 1 million deaths in the year 2000.5 organization. The U.S. Preventive Services Task Although there are other important risk factors Force (USPSTF) gave lung cancer screening a “D” for lung cancer,3,6–10 cigarette smoking is the major recommendation in both 1985 and 1996, meaning risk factor; approximately 87% of all lung, that there were fair-quality data to recommend bronchial, and tracheal cancer are attributed to against screening for lung cancer1 based largely on 3 smoking.3 Consequently, the most important public negative trials conducted in the United States in the health intervention that could reduce lung cancer 1970s. Since the last Task Force review, several new incidence and deaths is changing smoking habits. studies of lung cancer screening have been reported, Unfortunately, although overall prevalence rates of and greater attention has been directed toward the smoking in the United States have decreased over limitations of existing literature. This review was the past 2 decades, the prevalence of current adult conducted to aid the current USPSTF in updating smokers remains high at 24%.10,11 In the clinical its lung cancer screening recommendation. setting, -
Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S
Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD, MACG1, C. Richard Boland, MD2, Jason A. Dominitz, MD, MHS3, Francis M. Giardiello, MD4, David A. Johnson, MD, MACG5, Tonya Kaltenbach, MD, FACG6, Theodore R. Levin, MD, FACG7, David Lieberman, MD, FACG8 and Douglas J. Robertson, MD, MPH9 1Indiana University School of Medicine, Indianapolis, Indiana, USA; 2University of California San Diego, San Diego, California, USA; 3VA Puget Sound Health Care System, University of Washington, Seattle, Washington, USA; 4Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5Eastern Virginia Medical School, Norfolk, Virginia, USA; 6San Francisco Veterans Affairs Medical Center, San Francisco, California, USA; 7Kaiser Permanente Medical Center, Walnut Creek, California, USA; 8Oregon Health and Science University, Portland, Oregon, USA; 9VA Medical Center, White River Junction, Vermont, and Geisel School of Medicine at Dartmouth, Hanover, New Hampshire Am J Gastroenterol advance online publication 6 June 2017; doi: 10.1038/ajg.2017.174 Abstract This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi- Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy. -
Prostate Cancer Screening NATIONAL GUIDELINE SUMMARY the Guideline Was Developed Using an Evidence-Based Methodology
Prostate Cancer Screening NATIONAL GUIDELINE SUMMARY The guideline was developed using an evidence-based methodology. This guideline summary is intended to guide health care professionals with prostate cancer screening in asymptomatic adult men. It does not apply to men who have signs or symptoms of prostate disease, or in whom a diagnosis has already been made. PROSTATE CANCER SCREENING AND Men with an elevated PSA have approximately a 70% chance of having a prostate biopsy that is negative for SHARED DECISION-MAKING cancer. • For average risk men, offer prostate cancer screening If a cancer is detected, it may or may not ever become with prostate-specifi c antigen (PSA) testing and digital clinically signifi cant3 in a man’s lifetime. rectal examination (DRE) in the context of a shared If diagnosed, the grade and stage of the cancer determines decision-making approach starting at age 50. the likely effectiveness of treatment. Potential benefi ts • For higher risk men (i.e., black/African-American of prostate cancer treatments may include increased life descent, family history of at least one fi rst degree span, and reduction in morbidity from locally advanced and relative with prostate cancer), offer prostate cancer metastatic disease. Prostate cancer treatments may also screening with PSA and DRE in the context of a shared have potential complications. Some men with prostate decision-making approach starting at age 40. cancer may elect not to be treated after discussion with their urologist. • Prostate cancer screening is not recommended for men age 75 or older. IF SCREENING IS REQUESTED • In the shared decision-making approach, include • For men who elect to participate in prostate cancer information regarding the potential benefi ts and risks screening: of undergoing screening for prostate cancer. -
Medicalisation and Overdiagnosis: What Society Does to Medicine Wieteke Van Dijk*, Marjan J
http://ijhpm.com Int J Health Policy Manag 2016, 5(11), 619–622 doi 10.15171/ijhpm.2016.121 Perspective Medicalisation and Overdiagnosis: What Society Does to Medicine Wieteke van Dijk*, Marjan J. Faber, Marit A.C. Tanke, Patrick P.T. Jeurissen, Gert P. Westert Abstract The concept of overdiagnosis is a dominant topic in medical literature and discussions. In research that Article History: targets overdiagnosis, medicalisation is often presented as the societal and individual burden of unnecessary Received: 2 May 2016 medical expansion. In this way, the focus lies on the influence of medicine on society, neglecting the possible Accepted: 23 August 2016 influence of society on medicine. In this perspective, we aim to provide a novel insight into the influence of ePublished: 31 August 2016 society and the societal context on medicine, in particularly with regard to medicalisation and overdiagnosis. Keywords: Medicalisation, Overdiagnosis, Society Copyright: © 2016 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. *Correspondence to: Citation: van Dijk W, Faber MJ, Tanke MA, Jeurissen PP, Westert GP. Medicalisation and overdiagnosis: Wieteke van Dijk what society does to medicine. Int J Health Policy Manag. 2016;5(11):619–622. doi:10.15171/ijhpm.2016.121 -
Preventive Health Care
PREVENTIVE HEALTH CARE Understanding what’s covered What is preventive care? What’s not considered preventive care? Preventive care is a specific group of services Once you have a symptom or your health care provider recommended when you don’t have any symptoms diagnoses a health issue, additional tests are not and haven’t been diagnosed with a related health considered preventive care. Also, you may receive issue. It includes your periodic wellness exam other medically appropriate services during a periodic (check-up) and specific tests, certain health wellness exam that are not considered preventive. screenings, and most immunizations. Most of these These services may be covered under your plan’s services typically can take place during the same visit. medical benefits, not your preventive care benefits. You and your health care provider will decide what This means you may be responsible for paying a preventive services are right for you, based on your: share or all of the cost. This may include your plan’s › Age deductible, copay or coinsurance amounts, depending on your plan. › Gender › Personal health history Which preventive services are covered? › Current health Many plans cover preventive care at no additional cost to you when you use a health care provider Why do I need preventive care? in your plan’s network. Use the provider directory on myCigna.com Preventive care can help you detect problems at early for a list of in-network health care stages, when they may be easier to treat. It can also providers and facilities. help you prevent certain illnesses and health conditions See the charts on the following pages for the services from happening. -
The American Cancer Society
M-US-00001673(v5.0) AN IMPORTANT ACTION. A BIG IMPACT. WHY IS CANCER SCREENING IMPORTANT? According to the American Cancer Society, approximately 608,570 Americans are expected to die from cancer in 2021.1 Regular screening can help find certain cancers early, when they are most likely to be treated successfully.1 Learn what screening tests the American Cancer Society recommends, when you should have them, and talk to a health care professional about the best screening plan for you. DID YOU KNOW? Detecting cancer early through screening reduces deaths from colorectal, breast, cervical, lung (among current and former heavy smokers), and likely prostate.1,2 − American Cancer Society WHAT IS CANCER SCREEN WEEK? Cancer Screen Week is a public health initiative founded by Genentech, the American Cancer Society, Stand Up To Cancer and Rally Health to increase awareness of the benefits of screening for early detection of certain cancers. This nationwide collaborative effort to raise awareness about recommended cancer screening occurs the first full week of December each year. HOW CAN I GET INVOLVED? • Visit www.CancerScreenWeek.org to learn more about the potentially life saving benefits of cancer screening and download helpful resources for talking with your doctor. • Spread the word about Cancer Screen Week and join the collective effort to help save more lives from cancer. WHO SHOULD BE SCREENED FOR CANCER? Screening refers to tests and exams used to find cancer in people who don't have symptoms. Early detection means finding and diagnosing cancer earlier than if a person would wait for symptoms to start. -
ACR Practice Parameter for Performance of Contrast Enhanced
The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields. The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. Revised 2018 (Resolution 34)* ACR PRACTICE PARAMETER FOR THE PERFORMANCE OF CONTRAST- ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care1. -
Hrsa Ccm: Breast Cancer Screening
BREAST CANCER SCREENING U. S. Department of Health and Human Services Health Resources and Services Administration April 2011 Breast Cancer Screening Contents HRSA CCM: BREAST CANCER SCREENING ......................................................................... 1 Measure Description ................................................................................................................. 1 Part 1: Introduction ................................................................................................................. 1 Performance Measurement: Breast Cancer Screening ........................................................... 4 Part 2: Characteristics for Success: Breast Cancer Screening ........................................... 8 Part 3: Implementation of HRSA CCM: Breast Cancer Screening ................................. 14 Critical Pathway for Breast Cancer Screening ...................................................................... 15 Factors That Impact the Critical Pathway ............................................................................. 19 Data Infrastructure: Breast Cancer Screening ...................................................................... 23 Data Infrastructure to Monitor the Performance Measure—An Overview .......................... 23 Implementation: Breast Cancer Screening ........................................................................... 24 Part 4: Improvement Strategies: Breast Cancer Screening .............................................. 30 What Changes Can an Organization -
An Overview on High Health Care Costs in the US, Overdiagnosis, and Health Care Value
An Overview on High Health Care Costs in the US, Overdiagnosis, and Health Care Value Michael Tjahjadi, M.D. James Stallworth, M.D. Disclosures Neither Dr. Tjahjadi nor Dr. Stallworth has any financial incentives or relationships to disclose. The Healthcare System of the US We may have heard the phrases: Our healthcare system is broken Our spending in healthcare is unsustainable The US spends 2.5 times as much on health care as peer nations Yet some US outcomes trail peer nations Highest infant mortality rate Highest obesity rate US worst among high income countries when measured by specific population health outcomes Fairbrother et al, Pediatrics, June 2015 Ice-Breaker Question Is it too conflictual to ask clinicians to be cost-conscious and at the same time keep the welfare of the patient foremost in their minds? Yes No It depends Illustrative Case #1 15 year old AA male with SS trait presents with a 20 pound weight loss over 3 months despite an “ok” appetite. No change in bowel habits, no fever. He denies sexual activity and drug use, no history of blood transfusions and no other symptoms. He denies being depressed. On PE, he is quite thin with decreased subcutaneous tissue. His VS are stable but a HR of 110. He has no thrush, lymphadenopathy or HSM. He is Tanner 3. His exam is otherwise non revealing. From a health care value perspective, would you order an HIV? Illustrative Case #2 In June, a 22 mo previously healthy child presents with a 2 day history of diarrhea, 1 day of which is now bloody.